Due to the predominance of up regulated proteins involved in VEGF signalling in MPM, we analysed VEGFA levels in effusions and found a strong correlation between VEGFA levels and survival in MPM.
Importantly, unlike bevacizumab, nintedanib demonstrated significant <i>in vivo</i> antivascular and antitumor potential independently of baseline VEGF-A levels.<b>Conclusions:</b> Nintedanib exerts significant antitumor activity in MPM both <i>in vitro</i> and <i>in vivo</i> These data provide preclinical support for the concept of LUME-Meso trials evaluating nintedanib in patients with unresectable MPM.<i></i>.
Our results indicate that VEGF-CRAd exerts an oncolytic effect on MM cells and that intrapleural instillation of VEGF-CRAd is safe and might represent a promising therapeutic strategy for MPM.
We studied 37 patients with malignant pleural mesothelioma and found that 36 out of 37 (97.3%) malignant mesothelioma samples were stained positively for VEGF.